What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...
The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...
Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...
Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...
A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback